Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-CPT2 Antibody (3I417) is a Rabbit antibody targeting CPT2. Anti-CPT2 Antibody (3I417) can be used in WB,ICC/IF,IHC.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
50 μL | $298 | 7-10 days | |
100 μL | $496 | 7-10 days |
Description | Anti-CPT2 Antibody (3I417) is a Rabbit antibody targeting CPT2. Anti-CPT2 Antibody (3I417) can be used in WB,ICC/IF,IHC. |
Ig Type | IgG |
Reactivity | Human,Mouse,Rat |
Application | |
Recommended Dose | WB: 1:500-1000; IHC: 1:50-200; ICC/IF: 1:50-200 |
Antibody Type | Monoclonal |
Host Species | Rabbit |
Construction | Recombinant Antibody |
Purification | ProA affinity purified |
Appearance | Liquid |
Formulation | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
Research Background | The mitochondrial β-oxidation of long-chain fatty acids is initiated by the sequential action of carnitine palmitoyltransferase (CPT) I (outer membrane and detergent labile) and II (inner membrane and detergent stable), together with carnitine carrier. CPTI catalyzes the first reaction in the transport of long-chain fatty acids from the cytoplasm to the mitochondrion, a rate-limiting step in beta-oxidation. Two types of CPTI are known, the liver (CPTIA) and muscle (CPTIB) isoforms. The muscle type protein is specially expressed in heart and skeletal muscle. Membrane-bound CPTI, but not CPTII, is inhibited reversibly by malonyl-coenzyme A (CoA). Unlike CPTII, CPTI requires membrane integrity for catalytic function. In addition, glutamic acid 3 and histidine 5 are necessary for malonyl CoA inhibition and binding to liver CPTI, but not for catalytic activity. |
Conjucates | Unconjugated |
Immunogen | Recombinant Protein |
Antigen Species | Recombinant Protein |
Uniprot ID |
Molecular Weight | Theoretical: 74 kDa. |
Stability & Storage | Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.